Objective: To detect and classify features of stigmatizing and biased language in intensive care electronic health records (EHRs) using natural language processing techniques.
Materials And Methods: We first created a lexicon and regular expression lists from literature-driven stem words for linguistic features of stigmatizing patient labels, doubt markers, and scare quotes within EHRs. The lexicon was further extended using Word2Vec and GPT 3.5, and refined through human evaluation. These lexicons were used to search for matches across 18 million sentences from the de-identified Medical Information Mart for Intensive Care-III (MIMIC-III) dataset. For each linguistic bias feature, 1000 sentence matches were sampled, labeled by expert clinical and public health annotators, and used to supervised learning classifiers.
Results: Lexicon development from expanded literature stem-word lists resulted in a doubt marker lexicon containing 58 expressions, and a stigmatizing labels lexicon containing 127 expressions. Classifiers for doubt markers and stigmatizing labels had the highest performance, with macro F1-scores of 0.84 and 0.79, positive-label recall and precision values ranging from 0.71 to 0.86, and accuracies aligning closely with human annotator agreement (0.87).
Discussion: This study demonstrated the feasibility of supervised classifiers in automatically identifying stigmatizing labels and doubt markers in medical text and identified trends in stigmatizing language use in an EHR setting. Additional labeled data may help improve lower scare quote model performance.
Conclusions: Classifiers developed in this study showed high model performance and can be applied to identify patterns and target interventions to reduce stigmatizing labels and doubt markers in healthcare systems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jamia/ocae310 | DOI Listing |
J Am Med Inform Assoc
December 2024
Department of Biomedical Informatics, School of Medicine, Emory University, Atlanta, GA 30322, United States.
Objective: To detect and classify features of stigmatizing and biased language in intensive care electronic health records (EHRs) using natural language processing techniques.
Materials And Methods: We first created a lexicon and regular expression lists from literature-driven stem words for linguistic features of stigmatizing patient labels, doubt markers, and scare quotes within EHRs. The lexicon was further extended using Word2Vec and GPT 3.
Clin Neuroradiol
December 2024
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary and Foothills Medical Centre, Calgary, AB, Canada.
Background & Purpose: Non-stenotic (< 50%) carotid plaques are increasingly recognized as a potential mechanism for ischemic stroke. We assessed the prevalence of such plaques in patients with low-risk neurologic events and evidence of DWI (Diffusion Weighted Imaging)-positive ischemia.
Methods: This is a post-hoc exploratory analysis from the DOUBT study, a prospective, observational, multicenter study of patients with low-risk transient or persistent minor focal neurological symptoms.
BJC Rep
August 2024
Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular & Integrative Biology, The University of Liverpool, Liverpool, UK.
Background: Blood-based biomarkers might help lung cancer diagnosis. A panel of serum tumour markers (TM) has been validated for hospital referrals due to clinical suspicion of lung cancer. We have compared plasma from a cohort enriched for early-stage lung cancer, including controls from a healthy population cohort.
View Article and Find Full Text PDFNeurol Ther
November 2024
Memory Clinic and Neurodegenerative Dementia Research Unit, University Hospital Policlinico Tor Vergata, University of Rome "Tor Vergata", Viale Oxford, 81, 00133, Rome, Italy.
Lecanemab (Leqembi, Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer's disease (AD) in several countries, including the US and Japan. However, the European Medicines Agency (EMA) recently issued a negative opinion on its marketing authorization, reflecting concerns over the clinical value and manageability of anti-amyloid treatments. This decision highlights the ongoing disconnect between research advancements and clinical practice, where the focus on biological markers over tangible clinical improvements remains contentious.
View Article and Find Full Text PDFBackground: Different detection platforms can lead to significant differences in the results of CA19-9. Here, a case of a 38-year-old male colon cancer patient who underwent CA19-9 testing on two platforms after surgery.
Methods: We first inspect the instrument to confirm its normal operation and good indoor quality control.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!